Business Angel investors finance Catherinn's proof of concept studies on SCLC immunotherapy

15 July 2021

Through the Investormatch network, Catherinn secured the equity funding for the proof-of-concept studies on Small Cell Lung Cancer immunotherapy with a group of five Business Angels.

We are very pleased to have the trust of our new shareholders to make this exciting step forwards in valorization of our patented technology towards a better life for SCLC patients.

Link to Investormatch interview Poonam Sharma (Business Development) and Thijs Veerman (CEO) in Dutch: